{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:35:02Z","timestamp":1794530102804,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cameroon\u2019s Expanded Program on Immunization (EPI) introduced the HPV vaccine into the routine immunization schedule in Cameroon in October 2020. However, coverage for this vaccine was just 20% by December 2022, prompting the government to adopt and implement a gender-neutral vaccination (GNV) from January 2023. The goal was to increase acceptance, reduce stigma, and improve vaccine coverage. This study aimed to assess the perceptions of key immunization stakeholders in Cameroon on the GNV approach to HPV vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A qualitative study was conducted from June to September 2024 using in-depth and semi-structured interviews to explore the perspectives of key stakeholders (policymakers, community leaders, and parents of girls aged 9\u201313 years) across three regions (South-West, North, and Centre) and the central level. Data were analyzed using thematic analysis, with manuscripts coded manually and managed using NVivo software to identify key themes. The research team ensured reliability through consensus discussions, and key quotes illustrating central findings were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 51 participants were interviewed. Participants observed that the inclusion of boys in the HPV vaccination program contributed to a positive shift in community perceptions, dispelled misconceptions, instilled a sense of equity to healthcare access, and enhanced overall vaccine acceptance. However, challenges related to limited resources, lingering misinformation, and hesitancy from parents, religious leaders, and healthcare workers hindered the effective implementation of the GNV approach. Participants emphasized the need for improved partnerships, sensitization strategies, integration with existing health programs, and sustained funding to enhance community understanding and increase vaccination uptake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, stakeholders viewed the GNV approach as effective for improving HPV vaccine acceptability and promoting equity but emphasized the need for continuous investments and stronger community engagement to address challenges like limited resources, misinformation, and hesitancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-026-26730-9","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T02:04:18Z","timestamp":1771812258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Perceptions of a gender-neutral approach to human papillomavirus (HPV) vaccination in Cameroon: a qualitative study"],"prefix":"10.1186","volume":"26","author":[{"given":"Shariffatou","family":"Iliassu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence","family":"Mbanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Budzi","family":"Ngenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom","family":"Ndoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Ateke","family":"Njoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget C.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nebongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilienne Carine","family":"Bieme-Ndi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njike Sibenu","family":"Derrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadrack","family":"Mngemane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tosin","family":"Ajayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure Anais","family":"Zultak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yauba","family":"Saidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"5","key":"26730_CR1","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","volume":"40","author":"OKUNADE KS","year":"2020","unstructured":"OKUNADE KS. Human Papillomavirus and Cervical Cancer. J Obstet Gynaecol J Inst Obstet Gynaecol. 2020;40(5):602\u20138.","journal-title":"J Obstet Gynaecol J Inst Obstet Gynaecol"},{"key":"26730_CR2","unstructured":"Cervical cancer. [cited 2025 Mar 11]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer"},{"key":"26730_CR3","unstructured":"Cancer Today. [cited 2024 Dec 18]. Available from: https:\/\/gco.iarc.who.int\/today\/"},{"key":"26730_CR4","unstructured":"Global strategy to. accelerate the elimination of cervical cancer as a public health problem. [cited 2024 Dec 18]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240014107"},{"issue":"12","key":"26730_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/vaccines9121413","volume":"9","author":"S Kamolratanakul","year":"2021","unstructured":"Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines. 2021;9(12):1413.","journal-title":"Vaccines"},{"issue":"5 Pt 1","key":"26730_CR6","first-page":"735","volume":"83","author":"E Rylander","year":"1994","unstructured":"Rylander E, Ruusuvaara L, Almstr\u00f6mer MW, Evander M, Wadell G. The absence of vaginal human papillomavirus 16 DNA in women who have not experienced sexual intercourse. Obstet Gynecol. 1994;83(5 Pt 1):735\u20137.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"26730_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1188\/06.CJON.559-560","volume":"10","author":"MR McLemore","year":"2006","unstructured":"McLemore MR, Gardasil. Introducing the new human papillomavirus vaccine. Clin J Oncol Nurs. 2006;10(5):559\u201360.","journal-title":"Clin J Oncol Nurs"},{"issue":"35","key":"26730_CR8","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1016\/j.vaccine.2014.06.064","volume":"32","author":"JG Ogembo","year":"2014","unstructured":"Ogembo JG, Manga S, Nulah K, Foglabenchi LH, Perlman S, Wamai RG, et al. Achieving high uptake of human papillomavirus vaccine in Cameroon: Lessons learned in overcoming challenges. Vaccine. 2014;32(35):4399\u2013403.","journal-title":"Vaccine"},{"key":"26730_CR9","unstructured":"Ministry of Public Health. DHIS2 immunisation portal. 2022. Available from: https:\/\/dhis-minsante-cm.org\/dhis-web-data-visualizer\/index.html"},{"issue":"11","key":"26730_CR10","doi-asserted-by":"publisher","first-page":"e068212","DOI":"10.1136\/bmjopen-2022-068212","volume":"12","author":"L Elit","year":"2022","unstructured":"Elit L, Ngalla C, Afugchwi GM, Tum E, Domgue JF, Nouvet E. Assessing knowledge, attitudes and belief toward HPV vaccination of parents with children aged 9\u201314 years in rural communities of Northwest Cameroon: a qualitative study. BMJ Open. 2022;12(11):e068212.","journal-title":"BMJ Open"},{"key":"26730_CR11","doi-asserted-by":"publisher","unstructured":"Haddison E, Tambasho A, Kouamen G, Ngwafor R. Vaccinators\u2019 Perception of HPV Vaccination in the Saa Health District of Cameroon. Front Public Health. 2022 Jan 10 [cited 2024 Dec 16];9. Available from: https:\/\/www.frontiersin.org\/journals\/public-health\/articles\/https:\/\/doi.org\/10.3389\/fpubh.2021.748910\/full","DOI":"10.3389\/fpubh.2021.748910\/full"},{"key":"26730_CR12","doi-asserted-by":"publisher","first-page":"860809","DOI":"10.3389\/fpubh.2022.860809","volume":"10","author":"LA Khosa","year":"2022","unstructured":"Khosa LA, Meyer JC, Motshwane FMM, Dochez C, Burnett RJ. Vaccine Hesitancy Drives Low Human Papillomavirus Vaccination Coverage in Girls Attending Public Schools in South Africa. Front Public Health. 2022;10:860809.","journal-title":"Front Public Health"},{"key":"26730_CR13","unstructured":"Pappano H. Women and Vaccines: Bridging the Gap for Gender Equity. Shot@Life. 2024 [cited 2025 Mar 14]. Available from: https:\/\/shotatlife.org\/2024\/10\/10\/women-and-vaccines\/"},{"key":"26730_CR14","unstructured":"Strategic Advisory Group of Experts on Immunization (SAGE). - April 2022. [cited 2024 Dec 18]. Available from: https:\/\/www.who.int\/news-room\/events\/detail\/2022\/04\/04\/default-calendar\/sage_meeting_april_2022"},{"key":"26730_CR15","unstructured":"Note de. Recommandation n\u00b0 009\/2022 du Groupe Technique Consultatif National pour la Vaccination (GTCNV) A\/s Priorit\u00e9 de recherche op\u00e9rationnelle sur la vaccination anti-HPV. 2022."},{"key":"26730_CR16","doi-asserted-by":"publisher","first-page":"h2016","DOI":"10.1136\/bmj.h2016","volume":"350","author":"JA Bogaards","year":"2015","unstructured":"Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJLM, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350:h2016.","journal-title":"BMJ"},{"key":"26730_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2407-13-10","volume":"13","author":"R Marty","year":"2013","unstructured":"Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer. 2013;13:10.","journal-title":"BMC Cancer"},{"issue":"6\u20137","key":"26730_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1177\/10105395241273296","volume":"36","author":"S Yangchen","year":"2024","unstructured":"Yangchen S, Felsher M, Acosta D, Sukarom I, Wu L, Phuntsho S, et al. Lessons Learned From Bhutan on extending Girls-Only HPV Vaccination Program to Boys: A Qualitative Study. Asia Pac J Public Health. 2024;36(6\u20137):580\u20138.","journal-title":"Asia Pac J Public Health"},{"key":"26730_CR19","doi-asserted-by":"publisher","unstructured":"NjohAA, Waheed D-EN, Kedakse TSNJ, Ebongue LJ, Kongnyuy EJ, Amani A, et al. Overcoming challenges and achieving high HPV vaccination uptake in Cameroon: lessons learned from a gender-neutral and single-dose program and community engagement. BMC Public Health. 2025;25(1):1696. https:\/\/doi.org\/10.1186\/s12889-025-22776-3.","DOI":"10.1186\/s12889-025-22776-3"},{"key":"26730_CR20","unstructured":"Cameroon. population 2024 - StatisticsTimes.com. [cited 2025 Apr 4]. Available from: https:\/\/statisticstimes.com\/demographics\/country\/cameroon-population.php"},{"key":"26730_CR21","unstructured":"Immunization Agenda. 2030. [cited 2024 Dec 12]. Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/strategies\/ia2030"},{"issue":"12","key":"26730_CR22","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/ijc.29082","volume":"136","author":"AR Giuliano","year":"2015","unstructured":"Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136(12):2752\u201360.","journal-title":"Int J Cancer"},{"key":"26730_CR23","doi-asserted-by":"publisher","first-page":"1067299","DOI":"10.3389\/fpubh.2023.1067299","volume":"11","author":"JA Dykens","year":"2023","unstructured":"Dykens JA, Peterson CE, Holt HK, Harper DM. Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally. Front Public Health. 2023;11:1067299.","journal-title":"Front Public Health"},{"issue":"5","key":"26730_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/vaccines9050496","volume":"9","author":"C Deignan","year":"2021","unstructured":"Deignan C, Swartz A, Cooper S, Colvin CJ. Stakeholders\u2019 Understandings of Human Papillomavirus (HPV) Vaccination in Sub-Saharan Africa: A Rapid Qualitative Systematic Review. Vaccines. 2021;9(5):496.","journal-title":"Vaccines"},{"issue":"2","key":"26730_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.vaccine.2020.10.089","volume":"39","author":"L Majed","year":"2021","unstructured":"Majed L, Bresse X, El Mouaddin N, Schmidt A, Daniels VJ, Pavelyev A, et al. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. Vaccine. 2021;39(2):438\u201346.","journal-title":"Vaccine"},{"key":"26730_CR26","unstructured":"HTA of extending the HPV. vaccination to boys | HIQA. [cited 2024 Dec 12]. Available from: https:\/\/www.hiqa.ie\/reports-and-publications\/health-technology-assessment\/hta-extending-hpv-vaccination-boys"},{"issue":"2","key":"26730_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/vaccines11020300","volume":"11","author":"I Osaghae","year":"2023","unstructured":"Osaghae I, Darkoh C, Chido-Amajuoyi OG, Chan W, Padgett Wermuth P, Pande M, et al. Healthcare Provider\u2019s Perceived Self-Efficacy in HPV Vaccination Hesitancy Counseling and HPV Vaccination Acceptance. Vaccines. 2023;11(2):300.","journal-title":"Vaccines"},{"issue":"7","key":"26730_CR28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/vaccines9070713","volume":"9","author":"C Lin","year":"2021","unstructured":"Lin C, Mullen J, Smith D, Kotarba M, Kaplan SJ, Tu P. Healthcare Providers\u2019 Vaccine Perceptions, Hesitancy, and Recommendation to Patients: A Systematic Review. Vaccines. 2021;9(7):713.","journal-title":"Vaccines"},{"key":"26730_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pvr.2017.09.001","volume":"4","author":"KE Gallagher","year":"2017","unstructured":"Gallagher KE, Howard N, Kabakama S, Mounier-Jack S, Burchett HED, LaMontagne DS, et al. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007\u20132016. Papillomavirus Res. 2017;4:72\u20138.","journal-title":"Papillomavirus Res"},{"issue":"1","key":"26730_CR30","doi-asserted-by":"publisher","first-page":"2402122","DOI":"10.1080\/21645515.2024.2402122","volume":"20","author":"D Bakare","year":"2024","unstructured":"Bakare D, Gobbo E, Akinsola KO, Bakare AA, Salako J, Hanson C, et al. Healthcare worker practices for HPV vaccine recommendation: A systematic review and meta-analysis. Hum Vaccines Immunother. 2024;20(1):2402122.","journal-title":"Hum Vaccines Immunother"},{"key":"26730_CR31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/1471-2458-12-370","volume":"12","author":"J Ladner","year":"2012","unstructured":"Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012;12:370.","journal-title":"BMC Public Health"},{"issue":"37","key":"26730_CR32","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1016\/j.vaccine.2013.06.016","volume":"31","author":"J Wigle","year":"2013","unstructured":"Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects. Vaccine. 2013;31(37):3811\u20137.","journal-title":"Vaccine"},{"key":"26730_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1741-7015-10-136","volume":"10","author":"R Hutubessy","year":"2012","unstructured":"Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, et al. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. BMC Med. 2012;10:136.","journal-title":"BMC Med"},{"key":"26730_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12913-016-1824-5","volume":"16","author":"J Ladner","year":"2016","unstructured":"Ladner J, Besson MH, Audureau E, Rodrigues M, Saba J. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009\u20132014. BMC Health Serv Res. 2016;16:575.","journal-title":"BMC Health Serv Res"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-26730-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:39:46Z","timestamp":1781635186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-26730-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["26730"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-26730-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Cameroon\u2019s National Ethics Committee for Human Health Research (CNERSH) (application number 2024\/06\/168666\/CE\/CNERSH\/SP) and was conducted in full accordance with the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all participants involved in the study and their confidentiality and anonymity were maintained through unique identifiers, with no personal names or contact information. All study methods were carried out in accordance with relevant guidance and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1043"}}